FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
FDA General

Former Deputy Commissioner Gottlieb Added to FDA Short List

President-elect Donald Trumps transition team reportedly adds former FDA deputy commissioner Scott Gottlieb to the short list of candidates for the to...

Human Drugs

BMS Pays $19.5 Million to Settle Abilify Off-label Charges

Bristol-Myers Squibb enters into a $19.5 million settlement agreement with 43 states to resolve allegations the company used false and misleading repr...

Human Drugs

Federal Drug Wholesaler Standards Sought

Five stakeholders reiterate positions and add new insights from an FDA meeting on progress made toward implementing product identification requirement...

Medical Devices

Groups Suggest Changes to Software 510(k) Guidance

Stakeholders say they appreciate an FDA draft guidance on when medical device software changes require a new 510(k) and offer proposed revisions.

Human Drugs

Supply Chain Suspect Product Guidance Out

FDA issues a guidance to help trading partners identify a suspect product and notify FDA and other trading partners.

Human Drugs

FDA Clears Exact Imaging Micro-Ultrasound System

FDA clears an Exact Imaging 510(k) for its ExactVu micro-ultrasound system for urological procedures.

Human Drugs

Support for Multi-Region Trial Guidelines

Stakeholders voice support for International Conference on Harmonization draft guidelines on multi-region clinical trials and make specific suggestion...

Government Wants SCOTUS Biosim Provision Review

The acting solicitor general says the Supreme Court should hear appeals by Amgen and Sandoz involving two key related provisions of the Biologics Pric...

Human Drugs

Mutual Reliance Initiative Expands Drug Inspections

FDA associate commissioner Dana Corrigan says FDA is partnering with European Union regulatory authorities to expand drug manufacturing inspections th...

Human Drugs

Praise for Biosim User Fee Agreement

Three industry stakeholders praise the agreement reached for reauthorization of the Biosimilars User Fee Act.